Drug intelligence / Profile preview

PRN-211

Development stage: Unknown
Lead developer: ProEn Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Parenteral

Overview

PRN-211 is a bispecific antibody drug conjugate (ADC) being developed by ProEn Therapeutics for the treatment of solid tumors. As an ADC, it combines the targeting capabilities of a bispecific antibody with a cytotoxic payload to selectively target and kill cancer cells. The drug is classified as an antineoplastic agent and immunoconjugate, with its mechanism of action described as immunomodulatory. It is currently in early research stages (discovery phase) and has not yet entered clinical trials[1][2].

Beyond the preview

Go deeper on PRN-211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRN-211.

Explore the full profile